Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.30 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
| ▸ | CA9 | Q16790 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL402805 | 0.84 | ALDH1A1 (0.39) | ALDH1A1PDK1NLRP3TP53CYP3A4 | |
| SCHEMBL17717991 | 0.80 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL20344000 | 0.78 | ALDH1A1 (0.41) | ALDH1A1PDK1NLRP3TP53CYP3A4 | |
| SCHEMBL22194032 | 0.78 | ALDH1A1 (0.41) | ALDH1A1PDK1NLRP3TP53CYP3A4 | |
| SCHEMBL18756620 | 0.78 | ALDH1A1 (0.41) | ALDH1A1PDK1NLRP3TP53CYP3A4 | |
| SCHEMBL15837077 | 0.77 | ALDH1A1 (0.43) | ALDH1A1PDK1NLRP3TP53CYP3A4 | |
| SCHEMBL16126994 | 0.77 | ALDH1A1 (0.43) | ALDH1A1PDK1NLRP3TP53CYP3A4 | |
| SCHEMBL3803240 | 0.75 | ALDH1A1 (0.62) | ALDH1A1PDK1NLRP3TP53CYP3A4 | |
| SCHEMBL3806824 | 0.75 | ALDH1A1 (0.62) | ALDH1A1PDK1NLRP3TP53CYP3A4 | |
| SCHEMBL12942089 | 0.75 | ALDH1A1 (0.39) | ALDH1A1PDK1NLRP3TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065153-A1 | AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF | SANOFI-AVENTIS (FR) | 2012-03-15 | — | — | US | disclosed |
| US-20070270354-A1 | Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof | SANOFI-AVENTIS (FR) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065153-A1 | AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF | HPSE, HAAO, HEXD | ALDH1A1 371/4885PDK1 2303/4885NLRP3 3837/4885 |
| US-20070270354-A1 | Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof | HPSE, HAAO, HEXD | ALDH1A1 364/4885PDK1 2277/4885NLRP3 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.